April 16, 2026 07:00 ET  | Source: Boehringer Ingelheim Limited This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS (zongertinib tablets) in treatment-naïve patients with advanced non-small cell lung […]

The Landmark 48th Session of the Prize Comes as the King Faisal Foundation Marks 50 Years of Impact April 15, 2026 15:19 ET  | Source: King Faisal Prize Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) — On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal

April 15, 2026 08:00 ET  | Source: Callio Therapeutics SEATTLE and SINGAPORE, April 15, 2026 (GLOBE NEWSWIRE) — Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) Annual Meeting 2026 (April 17-22, San

April 15, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026– Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim’s DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab’s DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently

April 15, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia

Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities April 14, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd SANTA BARBARA, Calif. and PARSIPPANY, N.J., April 14, 2026 (GLOBE NEWSWIRE) — Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable

April 14, 2026 07:00 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB). Regarding

April 13, 2026 08:00 ET  | Source: Revolution Medicines, Inc. REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic

April 13, 2026 06:00 ET  | Source: ProSomnus Sleep Technologies, Inc. SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂

April 13, 2026 03:51 ET  | Source: Boehringer Ingelheim Limited With the launch of LENZELTA®, Boehringer Ingelheim enhances its comprehensive mastitis portfolio, offering farmers and veterinarians effective solutions to keep their dairy cattle healthy and farms viable. The vaccine will be available in several countries in the European Union (EU) as of April 2026.  Mastitis is among the

April 09, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany – 9 April, 2026 – Boehringer Ingelheim today announced a clinical trial collaboration with BioNTech to evaluate a novel immuno‑oncology combination in extensive‑stage small cell lung cancer (ES-SCLC), one of the most aggressive and underserved forms of cancer. Under the agreement, BioNTech will supply pumitamig (BNT327/BMS‑986545), a PD‑L1/VEGF‑A

April 09, 2026 07:30 ET  | Source: Smith & Nephew UK Ltd Results from the first-ever randomized control trial for the REGENETEN Implant in partial–thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated

April 09, 2026 06:00 ET  | Source: Zymeworks Inc. • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional

April 09, 2026 04:00 ET  | Source: Boehringer Ingelheim Limited •    Ecuador aims to become one of the first rabies free countries in Latin America.•    Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. •    Boehringer Ingelheim announces critical support to the project at the international One Health Summit

The New Beauty-Led Hydration Brand Debuts Globally April 08, 2026 09:01 ET  | Source: iHerb Holdings, Inc. IRVINE, Calif., April 08, 2026 (GLOBE NEWSWIRE) — iHerb, one of the world’s largest online retailers specializing in health and wellness, today announced an exclusive international partnership with k2o, founded by Kylie Jenner. Through this partnership, iHerb will soon bring k2o’s drink